ArticleJACC. Case reports2026
Eosinophilic Cardiomyopathy in Eosinophilic Granulomatosis With Polyangiitis After Dupilumab Therapy.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Eosinophilia and the Heart: Evolving Concepts.Current cardiology reports · 2026Review
- Unmasking EGPA During Dupilumab Therapy.JACC. Case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDupilumab, an IL-4Rα antagonist used in type 2 inflammatory diseases, is associated with transient peripheral eosinophilia, yet progression to eosinophilic granulomatosis with polyangiitis (EGPA) remains rare. CASE SUMMARY: A 64-year-old man presented with acute chest pain, dyspnea, marked hypereosinophilia, elevated cardiac biomarkers, and systemic symptoms 3 months after dupilumab initiation. Echocardiography and cardiac magnetic resonance imaging demonstrated left ventricular dysfunction, and endomyocardial biopsy confirmed eosinophilic myocarditis. High-dose corticosteroids and cyclophosphamide led to rapid clinical improvement. DISCUSSION: This case shows severe eosinophilic myocarditis in the context of dupilumab therapy. Current literature suggests biologic therapy may unmask underlying EGPA rather than directly induce vasculitis, emphasizing the need for vigilance. TAKE-HOME MESSAGES: Dupilumab-associated eosinophilia warrants careful eosinophil monitoring. New systemic or cardiac symptoms should prompt evaluation for EGPA, using multimodality imaging with a low threshold for performing endomyocardial biopsy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.